<DOC>
	<DOCNO>NCT00112463</DOCNO>
	<brief_summary>This phase II trial study well depsipeptide ( romidepsin ) work treat patient metastatic unresectable soft tissue sarcoma . Drugs use chemotherapy , depsipeptide , work different way stop growth tumor cell , either kill cell stop dividing .</brief_summary>
	<brief_title>Depsipeptide ( Romidepsin ) Treating Patients With Metastatic Unresectable Soft Tissue Sarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate response rate metastatic unresectable soft tissue sarcomas single-agent depsipeptide . II . To estimate time progression metastatic unresectable soft tissue sarcomas single-agent depsipeptide . III . To evaluate scope extent acute toxicity associate single-agent depsipeptide give patient soft tissue sarcoma . OUTLINE : This multicenter study . Patients receive depsipeptide ( romidepsin ) intravenously ( IV ) 4 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 6 additional course beyond documentation CR . After completion study treatment , patient follow every 2 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Chondrosarcoma</mesh_term>
	<mesh_term>Hemangiosarcoma</mesh_term>
	<mesh_term>Hemangiopericytoma</mesh_term>
	<mesh_term>Fibrosarcoma</mesh_term>
	<mesh_term>Neurofibrosarcoma</mesh_term>
	<mesh_term>Mesenchymoma</mesh_term>
	<mesh_term>Histiocytoma</mesh_term>
	<mesh_term>Sarcoma , Alveolar Soft Part</mesh_term>
	<mesh_term>Histiocytoma , Benign Fibrous</mesh_term>
	<mesh_term>Histiocytoma , Malignant Fibrous</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>Histologically cytologically confirm soft tissue sarcoma ( STS ) , include , limited , follow histology : Gastrointestinal stromal tumor ( GIST ) Refractory imatinib mesylate Desmoplastic small round cell tumor Clear cell sarcoma Extraskeletal osteosarcoma* Extraskeletal Ewing 's sarcoma* Extraskeletal ( myxoid ) chondrosarcoma* Secondary STS ( e.g. , radiationinduced STS neurofibrosarcoma due neurofibromatosis ) allow Metastatic unresectable disease No standard curative therapy exist Patients GIST must receive progressed imatinib mesylate Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan No known brain metastasis Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 Performance status Karnofsky 50100 % More 3 month White blood cell ( WBC ) â¥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) â¤ 2.5 time upper limit normal ( ULN ) Bilirubin normal Creatinine &lt; 1.5 time ULN Creatinine clearance ≥ 60 mL/min QTc ≤ 480 msec No cardiac abnormality ( e.g. , congenital long QT syndrome ) No myocardial infarction within past year No history coronary artery disease ( e.g. , angina Canadian Class IIIV positive stress image study ) No cardiac ischemia ( ST depression &gt; 2 mm ) electrocardiogram ( ECG ) No New York Heart Association Class IIIV congestive heart failure Ejection fraction &gt; 50 % multi gated acquisition scan ( MUGA ) scan echocardiogram No history sustain ventricular tachycardia , ventricular fibrillation , Torsades de Pointes , cardiac arrest unless control automatic implantable cardioverter defibrillator No hypertrophic restrictive cardiomyopathy prior treatment cause No significant leave ventricular hypertrophy No uncontrolled hypertension ( i.e. , blood pressure ≥ 160/95 mm Hg ) No cardiac arrhythmia require antiarrhythmic medication Beta blocker calcium channel blocker allow Patients digitalis discontinue allow No Mobitz II second degree block without pacemaker ( first degree Mobitz I second degree block , bradyarrhythmias , sick sinus syndrome require Holter monitoring evaluation cardiology ) No uncontrolled dysrhythmia No poorly control angina No cardiac disease No history allergic reaction attribute compound similar chemical biological composition FR901228 No ongoing active infection No iatrogenic immune deficiency immune deficiency secondary underlie disorder Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Potassium ≥ 4.0 mmol/L Magnesium ≥ 2.0 mg/dL No uncontrolled illness No psychiatric illness social situation would preclude study compliance No concurrent anticancer biologic agents No 1 prior chemotherapy regimen sarcoma Adjuvant chemotherapy precede disease relapse consider 1 prior chemotherapy regimen Patients GIST may receive 3 prior chemotherapy regimen comprise imatinib mesylate and/or sunitinib malate provide chemotherapy agent use No prior FR901228 ( depsipeptide ) At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No prior cumulative doxorubicin dose &gt; 500 mg/m^2 No concurrent anticancer chemotherapy At least 4 week since prior radiotherapy No concurrent anticancer radiotherapy At least 4 week since prior surgery No prior organ transplantation Recovered prior therapy No concurrent medication cause QTc prolongation No concurrent combination highly active antiretroviral therapy HIVpositive patient No concurrent drug know histone deacetylase inhibitor activity ( e.g. , sodium valproate ) No concurrent investigational agent No concurrent anticancer agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>